Human TRAILR1/TNFRSF10A Antibody

Catalog # Availability Size / Price Qty
MAB347-SP
MAB347-500
MAB347-100
TRAILR1/TNFRSF10A in Human Tonsil Tissue.
1 Image
Product Details
Citations (23)
FAQs
Supplemental Products
Reviews (1)

Human TRAILR1/TNFRSF10A Antibody Summary

Species Reactivity
Human
Specificity
Detects recombinant human TRAIL R1/TNFRSF10A in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant human (rh) TRAIL R2, rhTRAIL R3, rhTRAIL R4, or rhDcR3 is observed.
Source
Monoclonal Mouse IgG1 Clone # 69036
Purification
Protein A or G purified from hybridoma culture supernatant
Immunogen
S. frugiperda insect ovarian cell line Sf 21-derived recombinant human TRAIL R1/TNFRSF10A
Ala24-Asn239
Accession # AAC51226
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Label
Unconjugated

Applications

Recommended Concentration
Sample
Flow Cytometry
2.5 µg/106 cells
HeLa human cell line
Immunohistochemistry
1-25 µg/mL
See below
CyTOF-ready
Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.
 

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Data Example

Immunohistochemistry TRAILR1/TNFRSF10A in Human Tonsil Tissue. View Larger

TRAILR1/TNFRSF10A in Human Tonsil Tissue. TRAILR1/TNFRSF10A was detected in immersion fixed paraffin-embedded sections of human tonsil tissue using Mouse Anti-Human TRAILR1/TNFRSF10A Monoclonal Antibody (Catalog # MAB347) at 1.7 µg/mL for 1 hour at room temperature followed by incubation with the Anti-Mouse IgG VisUCyte™ HRP Polymer Antibody (Catalog # VC001). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic (Catalog # CTS013). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to cell surface on lymphocytes. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents.

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Preparation and Storage

Reconstitution
Reconstitute at 0.5 mg/mL in sterile PBS.
Reconstitution Buffer Available
Reconstitution Buffer 1 (PBS)
Catalog #
Availability
Size / Price
Qty
RB01
Shipping
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: TRAILR1/TNFRSF10A

Human TRAIL R1, also called DR4, is a type 1, TNF R family, membrane protein which is a receptor for TRAIL (APO2 ligand). In the TNF superfamily nomenclature, TRAIL RI is referred to as TNFRSF10A. TRAIL R1 cDNA encodes a 468 amino acid precursor protein containing extracellular cysteine-rich domains, a transmembrane domain and a cytoplasmic death domain. Among the TNF receptor family proteins, TRAIL R1 is most closely related to TRAIL R2/DR5, sharing 55% amino acid sequence identity. Binding of trimeric TRAIL to TRAIL R1 induces apoptosis. The induction of apoptosis likely requires oligomerization of the receptor. The human TRAIL R1/Fc chimera neutralizes the ability of TRAIL to induce apoptosis. Besides TRAIL R1, an additional TRAIL R2/DR5, which tranduces apoptosis signal, and two TRAIL decoy receptors, which antagonize TRAIL-induced apoptosis, have been reported.

References
  1. Pan, G. et al. (1997) Science 276:111.
  2. Golstein, P. (1997) Curr. Biol. 7:R750.
Long Name
TRAIL Receptor 1
Entrez Gene IDs
8797 (Human)
Alternate Names
APO2; CD261 antigen; CD261; cytotoxic TRAIL receptor; Death receptor 4; DR4 TRAIL receptor 1; DR4; TNF-related apoptosis inducing ligand receptor 1; TNF-related apoptosis-inducing ligand receptor 1; TNFRSF10A; TRAIL R1; TRAILR1; TRAIL-R1; TRAILR-1; TRAILR1MGC9365; tumor necrosis factor receptor superfamily member 10A; tumor necrosis factor receptor superfamily, member 10a

Product Datasheets

You must select a language.

x

Citations for Human TRAILR1/TNFRSF10A Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

23 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Marizomib sensitizes primary glioma cells to apoptosis induced by a latest-generation TRAIL receptor agonist
    Authors: C Boccellato, E Kolbe, N Peters, V Juric, G Fullstone, M Verreault, A Idbaih, MLM Lamfers, BM Murphy, M Rehm
    Cell Death & Disease, 2021;12(7):647.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  2. CD154 inhibits death of T cells via a Cis interaction with the alpha5beta1 integrin
    Authors: M Bachsais, S Salti, K Zaoui, GS Hassan, F Aoudjit, W Mourad
    PLoS ONE, 2020;15(8):e0235753.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  3. Stress-induced TRAILR2 expression overcomes TRAIL resistance in cancer cell spheroids
    Authors: D Stöhr, JO Schmid, TB Beigl, A Mack, DS Maichl, K Cao, B Budai, G Fullstone, RE Kontermann, TE Mürdter, SWG Tait, C Hagenloche, N Pollak, P Scheurich, M Rehm
    Cell Death Differ., 2020;0(0):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  4. Bcl-2-mediated control of TRAIL-induced apoptotic response in the non-small lung cancer cell line NCI-H460 is effective at late caspase processing steps
    Authors: L Danish, D Imig, F Allgöwer, P Scheurich, N Pollak
    PLoS ONE, 2018;13(6):e0198203.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  5. Targeting Apoptotic Activity Against Prostate Cancer Stem Cells
    Authors: D Jaworska, E Szliszka
    Int J Mol Sci, 2017;18(8):.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  6. Caspase-8 expression is predictive of tumour response to death receptor 5 agonist antibody in Ewing's sarcoma.
    Authors: Kang Z, Goldstein S, Yu Y, Meltzer P, Loeb D, Cao L
    Br J Cancer, 2015;113(6):894-901.
    Species: Human
    Sample Types: Whole Cells
    Applications: Functional Assay
  7. TRAIL-engineered bone marrow-derived mesenchymal stem cells: TRAIL expression and cytotoxic effects on C6 glioma cells.
    Authors: Tang X, Lu J, Tu H, Huang K, Fu R, Cao G, Huang M, Cheng L, Dai L, Zhang L
    Anticancer Res, 2014;34(2):729-34.
    Species: Rat
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  8. Crosstalk between mitochondrial ROS and depolarization in the potentiation of TRAIL-induced apoptosis in human tumor cells.
    Authors: Suzuki-Karasaki M, Ochiai T, Suzuki-Karasaki Y
    Int J Oncol, 2014;44(2):616-28.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  9. Dominant negative effects of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 4 on TRAIL receptor 1 signaling by formation of heteromeric complexes.
    Authors: Neumann S, Hasenauer J, Pollak N, Scheurich P
    J Biol Chem, 2014;289(23):16576-87.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  10. Exosomes secreted by human placenta carry functional Fas ligand and TRAIL molecules and convey apoptosis in activated immune cells, suggesting exosome-mediated immune privilege of the fetus.
    Authors: Stenqvist A, Nagaeva O, Baranov V, Mincheva-Nilsson L
    J Immunol, 2013;191(11):5515-23.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  11. Casticin potentiates TRAIL-induced apoptosis of gastric cancer cells through endoplasmic reticulum stress.
    Authors: Zhou Y, Tian L, Long L, Quan M, Liu F, Cao J
    PLoS ONE, 2013;8(3):e58855.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  12. The transmembrane domains of TNF-related apoptosis-inducing ligand (TRAIL) receptors 1 and 2 co-regulate apoptotic signaling capacity.
    Authors: Neumann S, Bidon T, Branschadel M, Krippner-Heidenreich A, Scheurich P, Doszczak M
    PLoS ONE, 2012;7(8):e42526.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  13. TRAIL-engineered pancreas-derived mesenchymal stem cells: characterization and cytotoxic effects on pancreatic cancer cells.
    Cancer Gene Ther., 2012;19(9):652-8.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  14. Drozitumab, a human antibody to death receptor 5, has potent antitumor activity against rhabdomyosarcoma with the expression of caspase-8 predictive of response.
    Authors: Kang Z, Chen J, Yu Y, Li B, Sun S, Zhang B, Cao L
    Clin Cancer Res, 2011;17(10):3181-92.
    Species: Human
    Sample Types: Whole Cells
    Applications: Functional Assay
  15. Dexamethasone counteracts the anti-osteoclastic, but not the anti-leukemic, activity of TNF-related apoptosis inducing ligand (TRAIL).
    Authors: Zauli G, Rimondi E, Celeghini C, Milani D, Secchiero P
    J. Cell. Physiol., 2010;222(2):357-64.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  16. Plasmacytoid dendritic cells express TRAIL and induce CD4+ T-cell apoptosis in HIV-1 viremic patients.
    Authors: Stary G, Klein I, Kohlhofer S, Koszik F, Scherzer T, Mullauer L, Quendler H, Kohrgruber N, Stingl G
    Blood, 2009;114(18):3854-63.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  17. Differential responses of FLIPLong and FLIPShort-overexpressing human myeloid leukemia cells to TNF-alpha and TRAIL-initiated apoptotic signals.
    Authors: Seal S, Hockenbery DM, Spaulding EY, Kiem HP, Abbassi N, Deeg HJ
    Exp. Hematol., 2008;36(12):1660-72.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  18. Diallyl trisulfide increases the effectiveness of TRAIL and inhibits prostate cancer growth in an orthotopic model: molecular mechanisms.
    Authors: Shankar S, Chen Q, Ganapathy S, Singh KP, Srivastava RK
    Mol. Cancer Ther., 2008;7(8):2328-38.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  19. Differential effects of chemotherapeutic drugs versus the MDM-2 antagonist nutlin-3 on cell cycle progression and induction of apoptosis in SKW6.4 lymphoblastoid B-cells.
    Authors: Barbarotto E, Corallini F, Rimondi E, Fadda R, Mischiati C, Grill V, Vaccarezza M, Celeghini C
    J. Cell. Biochem., 2008;104(2):595-605.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  20. A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis.
    Authors: Weinmann L, Wischhusen J, Demma MJ, Naumann U, Roth P, Dasmahapatra B, Weller M
    Cell Death Differ., 2008;15(4):718-729.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  21. P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells.
    Authors: Toscano F, Fajoui ZE, Gay F, Lalaoui N, Parmentier B, Chayvialle JA, Scoazec JY, Micheau O, Abello J, Saurin JC
    Oncogene, 2008;27(30):4161-71.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  22. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage.
    Authors: Dunn C, Brunetto M, Reynolds G, Christophides T, Kennedy PT, Lampertico P, Das A, Lopes AR, Borrow P, Williams K, Humphreys E, Afford S, Adams DH, Bertoletti A, Maini MK
    J. Exp. Med., 2007;204(3):667-80.
    Species: Human
    Sample Types: Whole Tissue
    Applications: IHC-P
  23. HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma.
    Authors: Singh TR, Shankar S, Srivastava RK
    Oncogene, 2005;24(29):4609-23.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry

FAQs

No product specific FAQs exist for this product, however you may

View all Antibody FAQs

Isotype Controls

Reconstitution Buffers

Secondary Antibodies

Reviews for Human TRAILR1/TNFRSF10A Antibody

Average Rating: 4 (Based on 1 Review)

5 Star
0%
4 Star
100%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used Human TRAILR1/TNFRSF10A Antibody?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Human TRAIL R1/TNFRSF10A Antibody
By Anonymous on 07/23/2018
Application: WB Sample Tested: HT-29 human colon adenocarcinoma cell line,MCF-7 human breast cancer cell line Species: Human

Total cell lysates from HT29 and MCF-7 were subjected to western blot. PVDF membrane were probed with 1 um/ml Human DR4 Antibody (MAB347). A specific band was detected for DR4 at approximately 55 kDa. This experiment was conducted under reducing conditions.